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Since the publication of the draft Human Genome 
and the subsequent UK Government White Paper 
Our inherence, our future  (2003) , there has been 
a surge activity around the development and 
provision of genetic testing services in the NHS. 
Building on a doctoral study (Hopkins 2004) of 
the evolution of genetic testing in the UK, this 
poster utilises a National System of Innovation 
framework (Cf. Lacasa, et al. 2004) to chart key 
changes to socio-technical system for UK genetic 
testing.  
Figure 1 sets out the key domains of a national 
system of innovation relevant for high 
technology: The base of knowledge and skills, 
demand/ social acceptability, industry, and 
finance. Importantly, historically, genetic testing 
has not relied on all of these domains to reach the 
clinic.  Instead the emergence of UK genetic 
testing technologies has been characterized as a 
‘hidden’ innovation system (Hopkins 2004 & 
2006, NESTA 2006) where governance of 
innovation takes place within an internal regime 
(dependent on informal self-regulation, ad-hoc 
funding, and bottom-up initiatives) within  
hospital-centred networks of researchers, 
specialist clinicians, charities and later clinical 
scientists and professional bodies representing 
the aforementioned groups (See white box by 
point 1 in Figure 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This poster illustrates how, in recent years, 
construction of a new external regime (including 
laws, regulations, social norms) has  commenced to 
accommodate the positions of wider groups (e.g. 
policy makers, commercial providers, primary care 
professionals) , transforming the socio-technical 
system for genetic testing and making its 
problematisation processes (Blume 1992)  more 
politicised, scrutinised and mainstream than in the 
previous internal regime. Robertson (2007) suggests 
these changes represent a shift in the governance 
model, disrupting the established innovation system 
as the existing expert-elite are increasingly have to 
share power over the technology.  
The most obvious signs of the construction of an 
external regime followed Alan Millburn’s (then 
Secretary of State for Health) announcement, in 
2001, that a programme of investment was planned.  
He  said “I have learned a lot about both the 
potential and problems associated with developments 
in genetics….it is time for politicians and the public 
as well as scientists to engage with the 
issue”.(speech at International Centre for Life, 
19.04.01, Newcastle-upon-Tyne). The Government’s 
subsequent  initiatives described in the 2003 White 
Paper Our inheritance, our future attempted to 
support the new enlarged innovation system  by 
targeting a range of key processes shown in Figure 1 
(especially points 2, 3, 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 These include: The creation of the Genetic Knowledge 
Parks to aid translation of genetic research; Training and 
initiatives for medical staff; Greater co-ordination of the 
clinical testing laboratories through the establishment of 
the UK Genetic Testing Network; Increased support for 
screening services and commissioning of services amongst 
other activities. Other earlier efforts to establish key 
elements of the external regime for genetic testing such as 
the establishment of the Human Genome Commission and 
efforts to establish and maintain a moratorium on the use of 
genetic testing in insurance may be thought of as actions 
necessary to generate public trust (point 6).  
The Human Genetics Commission also have called for 
legal protection against genetic discrimination. This could 
provide reassurance to individuals and facilitate 
participation in genetic research (such as UK Biobank) and 
help to ensure patients are dissuaded from having tests that 
might benefit them or other members of their family. A 
public consultation on the ‘Single Equality Bill’ which 
move these proposals forward has recently finished.  
Since the1990s commercial efforts to identify and patent 
genes and offer testing services have led to the 
problematisation of further issues centred on Regulation  
(point 5), intellectual property rights and the related 
challenge of technology transfer (point 4). As commercial 
testing has grown (notably in the USA) concerns of a 
regulatory ‘gap’ in the external regime have emerged 
(Hogarth et al. forthcoming). Non-Governmental 
Organisations such as GeneWatch and Which? have 
become important actors in this debate, pushing for 
increasing tightening of the regulatory framework for in-
vitro diagnostic tests  - a major element of the external 
regime. There has also been much concern that innovation 
will be hindered by a proliferation of patents on disease 
genes (Kaye et al. 2007, Hopkins et al. 2007). In particular 
Kaye et al. suggest there is a need for an infrastructure to 
assist researchers in negotiating the legal aspects of 
technology transfer.   
Finally, with additional public sector funding for 
translation as yet unidentified (Hopkins 2007) , and a risk 
of market failure in the commercial incentivisation  to 
develop tests (Martin et al. 2006)  the mobilisation of 
sufficient capital from the UK private sector  remains a 
challenge (point 7). As the medical application of genetics 
has become of wider interest (and perhaps of more 
relevance to mainstream medicine), so the construction of 
the external regime as led to the generation and reshaping 
of institutions, practices and networks. We might speculate 
that the UK has now have developed a new field of 
politicogenetics (Cf. Patternson, 1998) where politics and 
genetics meet once again after a long period of separation 
due to the legacy of eugenics (Kevles 1985).   
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FIGURE 1: KEY ELEMENTS OF A NATIONAL SYSTEM OF INNOVATION
(Adapted from Lacasa, Reiss & Senker, Science and Public Policy October  2004.  p. 388.)
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